- Home
- DFIN vs NVAX Comparison
DFIN vs NVAX Comparison
Compare DFIN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- NVAX
- Stock Information
- Founded
- DFIN 1983
- NVAX 1987
- Country
- DFIN United States
- NVAX United States
- Employees
- DFIN N/A
- NVAX N/A
- Industry
- DFIN Other Consumer Services
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DFIN Consumer Discretionary
- NVAX Health Care
- Exchange
- DFIN Nasdaq
- NVAX Nasdaq
- Market Cap
- DFIN 1.6B
- NVAX 1.3B
- IPO Year
- DFIN N/A
- NVAX 1995
- Fundamental
- Price
- DFIN $56.30
- NVAX $7.90
- Analyst Decision
- DFIN Strong Buy
- NVAX Buy
- Analyst Count
- DFIN 3
- NVAX 7
- Target Price
- DFIN $68.67
- NVAX $14.29
- AVG Volume (30 Days)
- DFIN 237.6K
- NVAX 7.9M
- Earning Date
- DFIN 10-30-2025
- NVAX 08-06-2025
- Dividend Yield
- DFIN N/A
- NVAX N/A
- EPS Growth
- DFIN N/A
- NVAX N/A
- EPS
- DFIN 2.79
- NVAX 2.54
- Revenue
- DFIN $755,000,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- DFIN N/A
- NVAX $61.69
- Revenue Next Year
- DFIN $4.66
- NVAX N/A
- P/E Ratio
- DFIN $20.21
- NVAX $3.10
- Revenue Growth
- DFIN N/A
- NVAX 9.22
- 52 Week Low
- DFIN $37.80
- NVAX $5.01
- 52 Week High
- DFIN $70.55
- NVAX $15.22
- Technical
- Relative Strength Index (RSI)
- DFIN 49.54
- NVAX 51.27
- Support Level
- DFIN $55.00
- NVAX $7.23
- Resistance Level
- DFIN $57.13
- NVAX $10.64
- Average True Range (ATR)
- DFIN 1.17
- NVAX 0.46
- MACD
- DFIN 0.29
- NVAX -0.10
- Stochastic Oscillator
- DFIN 60.99
- NVAX 19.65
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.